Literature DB >> 9641885

Prognostic factors in ductal pancreatic cancer.

C J Yeo1, J L Cameron.   

Abstract

INTRODUCTION: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post-diagnosis.
CONCLUSION: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.

Entities:  

Mesh:

Year:  1998        PMID: 9641885     DOI: 10.1007/s004230050104

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  31 in total

1.  Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas.

Authors:  W Meyer; C Jurowich; M Reichel; B Steinhäuser; P H Wünsch; C Gebhardt
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

2.  Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection.

Authors:  Robert M Cannon; Ryan LeGrand; Ryaz B Chagpar; Syed A Ahmad; Rebecca McClaine; Hong Jin Kim; Christopher Rupp; Cliff S Cho; Adam Brinkman; Sharon Weber; Emily R Winslow; David A Kooby; Carrie K Chu; Charles A Staley; Ian Glenn; William G Hawkins; Alexander A Parikh; Nipun B Merchant; Kelly M McMasters; Robert C G Martin; Glenda G Callender; Charles R Scoggins
Journal:  HPB (Oxford)       Date:  2012-01-19       Impact factor: 3.647

Review 3.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 4.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

5.  Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor.

Authors:  Joseph E Kobes; Iman Daryaei; Christine M Howison; Jordan G Bontrager; Rachael W Sirianni; Emmanuelle J Meuillet; Mark D Pagel
Journal:  Pancreas       Date:  2016-09       Impact factor: 3.327

6.  Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma.

Authors:  E J Clark; S Connor; M A Taylor; K K Madhavan; O J Garden; R W Parks
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.

Authors:  Zhan Hua; Yuan-Chun Zhang; Xiao-Ming Hu; Zhen-Geng Jia
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

8.  Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.

Authors:  Luca Degrate; Cinzia Nobili; Claudio Franciosi; Roberto Caprotti; Fernando Brivio; Fabrizio Romano; Biagio Eugenio Leone; Rosangela Trezzi; Franco Uggeri
Journal:  Langenbecks Arch Surg       Date:  2008-08-01       Impact factor: 3.445

9.  Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas.

Authors:  Murray F Brennan; Michael W Kattan; David Klimstra; Kevin Conlon
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 10.  Strategies for early detection of resectable pancreatic cancer.

Authors:  Keiichi Okano; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.